NEOGENOMICS INC's ticker is NEO and the CUSIP is 64049M209. A total of 263 filers reported holding NEOGENOMICS INC in Q2 2023. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,230 | -23.5% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $1,607 | -7.7% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $1,741 | +88.4% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $924 | -7.6% | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 100 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $3,000 | -40.0% | 100 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $5,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $5,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -54.5% | 100 | -50.0% | 0.00% | -50.0% |
| Q4 2020 | $11,000 | +37.5% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $8,000 | +14.3% | 200 | 0.0% | 0.00% | +33.3% |
| Q2 2020 | $7,000 | +16.7% | 200 | 0.0% | 0.00% | -25.0% |
| Q1 2020 | $6,000 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kopp Family Office, LLC | 1,785,605 | $86,138,000 | 34.19% |
| PERKINS CAPITAL MANAGEMENT INC | 157,750 | $7,610,000 | 4.71% |
| Blue Water Life Science Advisors, LP | 222,222 | $10,719,000 | 3.49% |
| First Light Asset Management, LLC | 1,055,960 | $50,940,000 | 3.36% |
| Ranger Investment Management | 810,956 | $39,121,000 | 2.09% |
| Bullseye Asset Management LLC | 108,054 | $5,212,000 | 1.81% |
| Lombard Odier Asset Management (Switzerland) SA | 584,281 | $28,186,000 | 1.75% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 998,858 | $48,185,000 | 1.67% |
| EMERALD ADVISERS, LLC | 904,298 | $43,623,000 | 1.58% |
| Soleus Capital Management, L.P. | 190,556 | $9,192,000 | 1.43% |